Transdermal absorption of L-dopa from hydrogel in rats

European Journal of Pharmaceutical Sciences

Volumn 7, Issue 1, 1998, Pages 67-71

  Sudo, Jun ichi ^a   Iwase, Hiroaki ^b   Terui, Jun ^a   Kakuno, Katsuhiko ^a   Momoko Soyama, ^a   Takayama, Kozo ^b   Nagai, Tsuneji ^b  

^a Teikyo University   (Japan)

^b HOSHI UNIVERSITY   (Japan)

Author keywords

Ethanol; Hydrogel; L Dopa; L Menthol; Rat; Transdermal absorption

Indexed keywords

ADRENALIN; ALCOHOL; DOPAMINE; LEVODOPA; MENTHOL; NORADRENALIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HYDROGEL; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; TRANSDERMAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; ANIMALS; DOPAMINE; DOPAMINE AGENTS; EPINEPHRINE; HYDROGEL; INJECTIONS, INTRAVENOUS; LEVODOPA; MALE; NOREPINEPHRINE; RATS; RATS, WISTAR; SKIN ABSORPTION;

EID: 0032413712     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-0987(98)00007-4     Document Type: Article

References (14)

1. Ellenhorn, M.J., Barceloux, D.G., 1988. Medical Toxicology: Diagnosis and Treatment of Human Poisoning, Elsevier, New York, pp. 16.
2. Eriksson B.-M., Persson B.-A. Determination of catecholamines in rat heart tissue and plasma samples by liquid chromatography with electrochemical detection. J. Chromatogr. 228:1982;143-154.
3. Kato T., Wakui Y., Nagatsu T., Ohnishi T. An improved dual-wavelength spectrophotometric assay for dopamine-β-hydroxylase. Biochem. Pharmacol. 27:1978;829-831.
4. Levison K.K., Takayama K., Isowa K., Okabe K., Nagai T. Formulation optimization of indomethacin gels containing a combination of three kinds of cyclic monoterpenes as percutaneous penetration enhancers. J. Pharm. Sci. 83:1994;1367-1372.
5. Ohara N., Takayama K., Machida Y., Nagai T. Combined effect of D-limonene and temperature on the skin permeation of ketoprofen. Int. J. Pharm. 105:1994;31-38.
6. Okamoto H., Hashida M., Sezaki H. Structure-activity relationship of 1-alkyl- or 1-alkenylazacycloalkanone derivatives as percutaneous penetration enhancers. J. Pharm. Sci. 774:1988;418-424.
7. Quinn N.P. Anti-parkinsonian drugs today. Drugs. 28:1984;236-262.
8. Rahman M.K., Nagatsu T., Kato T. Aromatic L-amino acid decarboxylase activity in central and peripheral tissues and serum of rats with L-dopa and L-5-hydroxytryptophan as substrates. Biochem. Pharmacol. 30:1981;645-649.
9. Reimherr F.W., Wood D.R., Wender P.H. An open clinical trial of L-dopa and calbidopa in adults with minimal brain dysfunction. Am. J. Psychiatry. 137:1980;73-75.
10. Shoulson I., Glaubiger G.A., Chase T.N. On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology. 25:1975;1144-1148.
11. Sperk G., Galhaup I., Schlögl E., Hörtnagl H., Hornykiewicz O. A sensitive and reliable assay for dopamine β-hydroxylase in tissue. J. Neurochem. 35:1980;972-976.
12. Sudo J., Iwase H., Terui J., Hayashi T., Soyama M. Higher dopamine level in lymph from the cervical lymph trunk than in plasma following intravenous bolus injection of L-dopa in rats. Biol. Pharm. Bull. 18:1995;610-614.
13. 2]-angiotensin II in rats. Biol. Pharm. Bull. 17:1994;1516-1518.
14. Yamaoka K., Tanigawara Y., Nakagawa T., Uno T. A pharmacokinetic analysis program (MULTI) for micro-computer. J. Pharmacobio. Dyn. 4J. Pharmacobio. Dyn. 4:1981;879-885.